PT  - JOURNAL ARTICLE
ED - BMJ Publishing Group Ltd
TI  - ▼Varenicline for smoking cessation
AID  - 10.1136/dtb.2008.04.0010
DP  - 2008 May 01
TA  - Drug and Therapeutics Bulletin
PG  - 33--36
VI  - 46
IP  - 5
4099  - http://dtb.bmj.com/content/46/5/33.short
4100  - http://dtb.bmj.com/content/46/5/33.full
SO  - Drug Ther Bull2008 May 01; 46
AB  - Relevant BNF section: BNF 4.10▼Varenicline (pronounced va-re-nik-leen) (Champix – Pfizer), a nicotinic receptor partial agonist, is the first medicine of this type licensed for smoking cessation in adults. Launched in the UK in December 2006, the drug accounted for 14% of all prescription items and 22% of total expenditure, for smoking cessation products dispensed in the community in 2007*.1–4 Marketing materials claim that it has a “unique dual action”, a “significantly higher quit rate” than bupropion, and a “favourable safety and tolerability profile”. Here we discuss the evidence for varenicline and consider its role in smoking cessation.